380 related articles for article (PubMed ID: 30188287)
1. Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents.
Biancalana L; Pampaloni G; Marchetti F
Chimia (Aarau); 2017 Sep; 71(9):573-579. PubMed ID: 30188287
[TBL] [Abstract][Full Text] [Related]
2. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
3. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
4. Exploring pta Alternatives in the Development of Ruthenium-Arene Anticancer Compounds.
Kljun J; Rebernik M; Balsa LM; Kladnik J; Rapuš U; Trobec T; Sepčić K; Frangež R; León IE; Turel I
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985471
[TBL] [Abstract][Full Text] [Related]
5. Development of Arene Ruthenium Antitumor Complexes.
Su W; Tang Z; Li P
Mini Rev Med Chem; 2016; 16(10):787-95. PubMed ID: 27161008
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Activity and Modes of Action of (arene) ruthenium(II) Complexes Coordinated to C-, N-, and O-ligands.
Biersack B
Mini Rev Med Chem; 2016; 16(10):804-14. PubMed ID: 27161009
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
[TBL] [Abstract][Full Text] [Related]
8. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
9. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
10. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
11. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.
Yan YK; Melchart M; Habtemariam A; Sadler PJ
Chem Commun (Camb); 2005 Oct; (38):4764-76. PubMed ID: 16193110
[TBL] [Abstract][Full Text] [Related]
12. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
13. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
15. Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes.
Clavel CM; Păunescu E; Nowak-Sliwinska P; Griffioen AW; Scopelliti R; Dyson PJ
J Med Chem; 2015 Apr; 58(8):3356-65. PubMed ID: 25812075
[TBL] [Abstract][Full Text] [Related]
16. Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand.
Egger AE; Hartinger CG; Renfrew AK; Dyson PJ
J Biol Inorg Chem; 2010 Aug; 15(6):919-27. PubMed ID: 20364440
[TBL] [Abstract][Full Text] [Related]
17. Fine-tuning the cytotoxicity of ruthenium(II) arene compounds to enhance selectivity against breast cancers.
Pereira SAP; Romano-deGea J; Barbosa AI; Costa Lima SA; Dyson PJ; Saraiva MLMFS
Dalton Trans; 2023 Aug; 52(33):11679-11690. PubMed ID: 37552495
[TBL] [Abstract][Full Text] [Related]
18. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.
Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L
Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659
[TBL] [Abstract][Full Text] [Related]
19. Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo.
Mohamed Subarkhan MK; Ren L; Xie B; Chen C; Wang Y; Wang H
Eur J Med Chem; 2019 Oct; 179():246-256. PubMed ID: 31255925
[TBL] [Abstract][Full Text] [Related]
20. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]